Health
Health Ministry Aims to Regulate Antimicrobials Under New Drugs Rules
By PTI

The Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under the Central regulatory framework that applies to new drugs. The draft gazette notification, dated November 6, seeks to include antimicrobials in the definition of new drug under Rule 2(1)(w)(v). The move is intended to strengthen oversight of the quality, safety and efficacy of antimicrobial products and to address the global public health threat of antimicrobial resistance (AMR). The ministry noted that the G20 New Delhi Leaders' Declaration has highlighted the need to tackle AMR through a ‘One Health’ approach. It added that the amendment has been prompted by concerns that manufacturing licences for antimicrobial products are sometimes granted without adequate regulatory scrutiny, such as the absence of studies on bioavailability, bioequivalence and stability. The lack of such assessments could compromise product quality and safety, and substandard or ineffective antimicrobials may contribute to the spread of resistance, posing risks to patient safety. Under the proposed amendment, manufacturers would need to obtain permission from the Central Licensing Authority before applying for a manufacturing licence from the relevant State Licensing Authority. This is expected to enhance Central oversight and help ensure that antimicrobial products meet required standards. The draft notification invites objections and suggestions from stakeholders and the public before the amendment is finalized by the Centre. Antimicrobials are agents that kill microorganisms or inhibit their growth, including medicines used to treat or prevent infections and substances applied to skin or surfaces to reduce microbes.
Frequently asked questions
What is the proposed amendment to the New Drugs and Clinical Trials Rules, 2019?
The amendment would bring antimicrobials under the Central regulatory framework for new drugs by including them in the definition of new drug under Rule 2(1)(w)(v).
What changes will manufacturers face under the proposed amendment?
Manufacturers would need permission from the Central Licensing Authority before applying for a manufacturing licence from the relevant State Licensing Authority.
Why is the amendment being introduced?
To strengthen oversight of the quality, safety and efficacy of antimicrobial products and address the global public health threat of antimicrobial resistance (AMR).